Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age21+
SponsorMassachusetts General Hospital
About this trial
The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.
Eligibility criteria
Qualifiers
Female ≥ 21 years old
Diagnosis of early-stage (0-IIIb), hormone receptor positive (ER+/PR+) breast cancer
Completed primary treatment (surgery, chemotherapy, and/or radiation)
Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET)
Disqualifiers
Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist
Enrolled in a clinical trial for AET
Trial design
Treatments tested in this trial
- STRIDE
- Usual Care
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov